Schrödinger (SDGR) Q1 2026 Earnings Transcript

Schrödinger reported Q1 revenue of $58.6 million and ACV of $28.4 million, up 12% year over year, while maintaining full-year 2026 ACV guidance of $218 million to $228 million. Hosted software adoption improved to 34% of software revenue from 24% a year ago, though software gross margin fell to 69% from 80% and the company posted a $60 million net loss. A key catalyst is Eli Lilly’s $2.3 billion Ajax Therapeutics acquisition, in which Schrödinger owns about a 6% stake, alongside the summer launch of its Bunsen agentic AI product and encouraging clinical data from SGR3515 and SGR1505.

Analysis

SDGR is transitioning from a classic “beat-and-raise” story to a more interesting mix of de-risked software monetization and hidden balance-sheet optionality. The hosted-license shift is temporarily depressing recognized revenue and gross margin, but the second-order effect is better customer embedment: once workflows move to hosted and throughput-based pricing, switching costs rise and usage should compound faster than seat-based ARR would suggest. The near-term headline optics are weaker than the underlying demand signal, especially since new products and top-tier pharma penetration are doing the heavy lifting rather than just contract repricing.

The market is likely underappreciating how much the AI launch changes the monetization curve. Bunsen is not just a product feature; it is a usage amplifier that can convert dormant expert capacity into higher compute consumption, which should disproportionately benefit the software side if pricing migrates toward throughput. That creates a subtle but important positive loop: more automation increases platform throughput, which increases billable usage, which in turn reinforces hosted adoption and makes SDGR look less like a one-time software vendor and more like an infrastructure layer for discovery workflows.

On the therapeutics side, the Ajax transaction is a clean near-term catalyst but the larger implication is validation of SDGR’s repeated exit engine. The company’s willingness to stop pushing wholly owned assets into late-stage development is actually margin-positive over a multi-year horizon because it reduces internal capital intensity while preserving royalty and milestone exposure; that should improve the probability of reaching profitability without sacrificing upside. The main risk is that investors over-focus on lower reported margins and ignore the fact that the business is intentionally trading near-term recognition for higher-quality, more recurring revenue and optionality.

The contrarian view is that consensus may be too conservative on the pace of software acceleration and too linear on drug discovery volatility. If Q2 and Q3 show even modest continued migration to hosted plus early Bunsen traction, the stock could re-rate before the fuller financial benefit appears in 2027-2028 numbers. The key reversal risk is if hosted adoption slows after the easy renewals are done or if usage expansion proves less monetizable than management implies, which would leave investors owning a lower-margin software transition story without enough growth offset.

Key Decisions for Investors

• Go long SDGR on a 3-6 month horizon into any post-earnings pullback; the asymmetric setup is that margin compression is visible now, while hosted adoption and Bunsen monetization should show up later. Use a 2-3% portfolio risk budget and add only if ACV growth stays above the low-teens run rate.
• Buy SDGR calls 3-6 months out rather than common stock if liquidity allows; the catalyst path is clearer than the downside path, and the market is likely to reprice on evidence of accelerating hosted mix or early Bunsen uptake.
• Pair trade: long SDGR / short a basket of lower-quality biotech software names that lack recurring usage leverage. The relative call is that SDGR has both software and balance-sheet/M&A optionality, while peers are more exposed to linear budget recovery.
• Trim or avoid short exposure into the next 1-2 quarters; the risk is that the market starts capitalizing the hosted transition before GAAP numbers fully recover, leading to a squeeze on any underweight or short thesis built around near-term margin decline.
• Watch for confirmation in Q2/Q3 ACV and hosted mix; if hosted revenue approaches the high-30s share of software and ACV grows toward the top end of guidance, consider adding aggressively because that would validate the compounding thesis.